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ABSTRACT  20 
Fluoroquinolones (FQs) are photoreactive drugs, but it is not known whether laboratory 21 
light exposure can influence the induction of photoproducts and modify in vitro test 22 
results. The basophil activation test (BAT) has proven to be useful for evaluating IgE-23 
mediated hypersensitivity to FQs, with a higher percentage of positive responders with 24 
ciprofloxacin (CIP) than with moxifloxacin (MOX). We studied the effect of laboratory 25 
light on CIP and MOX degradation, and drug-protein conjugate formation, and its 26 
influence on the BAT for evaluating IgE-mediated hypersensitivity to FQs. The results 27 
showed an important decrease in the fluorescence emission intensity under light 28 
compared to dark conditions for MOX, and that BAT positivity was lower in light 29 
(17.9%) than in dark (35.7%). No changes were found for CIP in either fluorescence 30 
emission intensity or BAT results (46.4% in both conditions). We can conclude that 31 
light exposure is a critical factor in the BAT results when photolabile drugs like 32 
moxifloxacin are used. Therefore, light is important when interpreting in vitro results.  33 
  34 
 3 
INTRODUCTION 35 
Quinolones have been used for more than thirty years to treat a wide range of 36 
infections. Ultraviolet radiation induces their photodegradation, which is modulated by 37 
the nature and position of the substituents attached to the quinolone skeleton [1,2]. For 38 
example, the presence of a halogen, as in fluoroquinolones (FQs), seems to be 39 
associated with a higher phototoxic potential [3,4]. Photodecomposition may involve a 40 
variety of photochemical processes, such as generation of singlet oxygen, production 41 
of superoxide, defluorination, decarboxylation at C-3 or oxidation of the amino group at 42 
C-7 [1,2,4].  43 
Generally FQs are well tolerated [5], although the last decade has witnessed an 44 
increasing number of immediate hypersensitivity reactions (IHR) induced by FQs, with 45 
urticaria and anaphylaxis the most frequently reported reactions [6-8]. These 46 
observations, especially the occurrence of more severe reactions, have been 47 
associated with the introduction of moxifloxacin (MOX) for therapeutic use [6]. In fact, 48 
in a group of patients diagnosed with IHR to FQs, MOX was involved in more than 60% 49 
of the cases with more severe reactions, followed by ciprofloxacin (CIP) in 30% and, to 50 
a much lower extent, levofloxacin [8].  51 
Evidence supporting an IgE mechanism for IHR has been provided by the 52 
detection of specific antibodies, by both immunoassay and basophil activation tests 53 
(BAT), with different patterns of cross-reactivity among FQs [7,8]. Despite these 54 
findings, the true nature of the haptenic substructure (from the parent drug or its 55 
metabolites) recognized by the immune system remains unknown. The BAT is an 56 
adequate model for studying IgE-mediated reactions to FQs because, in addition to 57 
sensitized basophils, it enables study of the hapten, both free and protein bound, as 58 
well as its metabolites.  59 
Previous evidence from well-validated CIP and MOX IHR cases suggests that 60 
basophil activation occurs to CIP more often than to MOX, even in those cases where 61 
MOX was the culprit drug [8]. Because each FQ exhibits chemical differences, our 62 
hypothesis was that they may behave differently upon light exposure, which may 63 
influence the formation of drug-protein conjugates and therefore interfere with the 64 
basophil activation. To test this hypothesis we investigated how light exposure can 65 
affect the BAT results in patients with IgE-mediated hypersensitivity reactions and 66 
controls with good tolerance to these FQs.  67 
 68 
MATERIAL AND METHODS 69 
The stability of the FQs when exposed to laboratory light was checked by 70 
spectrophotometric and fluorometric measurements in an aqueous solution and in 71 
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supernatants obtained from the BAT. These supernatants were divided into high 72 
molecular weight fractions (>3000Da), containing the drug bound to the serum 73 
proteins, and low molecular weight fractions (<3000Da), with the free drug or its 74 
metabolites, before analysis.  75 
BAT was done as described [8] under light and dark conditions with whole 76 
blood from patients with confirmed immediate hypersensitivity to CIP (N=15) or MOX 77 
(N=13) and quinolone tolerant controls (N=20). Results were considered as positive 78 
when the stimulation index (SI), calculated as the ratio between the percentage of 79 
degranulated basophils with the haptens and the spontaneous basophil activation, was 80 
greater than 3. Detailed information about the photochemical and biological studies is 81 
available in the Supplemental Material. 82 
RESULTS 83 
Photostability of ciprofloxacin and moxifloxacin 84 
Absorption spectra of CIP and MOX showed a wide wavelength band reaching up to 85 
400 nm (Figure S1A Supplementary Material). Emission studies were performed by 86 
excitation at 320 nm and 337 nm for CIP and MOX, respectively, displaying different 87 
emission bands centered at 420 nm for CIP and 460 nm for MOX. Neither CIP nor 88 
MOX exhibited significant spectroscopic changes under light or dark conditions in 89 
aqueous solution, indicating a low photodegradation (Figure S1B). 90 
We then analyzed the effect of laboratory light on FQ degradation and on their 91 
capability to form drug-protein conjugates in whole blood, the medium used in BAT. 92 
The emission data of the low and high molecular weight fractions showed few, if any 93 
differences, in the fluorescence intensity for CIP under light or dark conditions, either in 94 
free or protein fractions (Figure 1). However, remarkable differences were observed for 95 
MOX in both fractions, with an important decrease in the fluorescence emission 96 
intensity upon light exposure, indicating drug photodegradation.  97 
 98 
BAT results 99 
Twenty-eight patients with confirmed IHR to CIP and MOX and 20 controls with 100 
confirmed good tolerance to FQs were evaluated (Table 1 and Supplemental Material). 101 
Figure 2 shows the dose response curve with four different concentrations of CIP and 102 
MOX, in light and dark in 16 allergic patients and 15 controls. The optimal 103 
concentrations were found to be 0.2 and 2 mg/mL for both drugs, and these 104 
concentrations were used throughout the study. 105 
Table 1 shows the results of the BAT for CIP and MOX in light and dark for the 106 
individual cases, with positive cases shown shaded. For CIP, BAT was positive in 13 107 
cases (46.4%) under light conditions and in 13 cases (46.4%) under dark conditions. 108 
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For MOX, BAT was positive in 5 (17.9%) under light conditions and in 10 (35.7%) 109 
under dark conditions. Results were positive to either of the two FQs in 13 cases 110 
(46.4%) under light conditions and in 16 cases (57.1%) under dark conditions. Figure 111 
S2 shows the dot-plot in light and dark of two representative cases.  112 
Analysis of the results depending on the FQ involved in the reaction showed 113 
that in those cases where CIP was the culprit drug (N=15), BAT was positive to CIP in 114 
5 (33.33%) in light conditions and 6 (40%) in dark; and to MOX in 6 (40%) in light and 4 115 
(26.66%) in dark; and to either of the two quinolones in 5 (33.33%) in light and 8 116 
(53.33%) in dark conditions. 117 
In those cases where MOX was the culprit drug (N=13), BAT was positive to 118 
CIP in 8 (61.53%) in light and 7 (53.84%) in dark; and to MOX in 2 (15.38%) in light 119 
and 6 (46.15%) in dark; and to either of the two FQs in 8 (61.53%) in both light and 120 
dark conditions.  121 
In controls (N=20), under light conditions, BAT was positive in 2 cases to CIP, 1 122 
case to MOX, and 2 cases to at least one FQ; and in dark, BAT was positive in 1 case 123 
to CIP, 2 cases to MOX, and 2 cases to at least one FQ. As a result, the specificity was 124 
90% in both light and dark. 125 
 126 
DISCUSSION 127 
The presence of IgE antibodies to FQs has been demonstrated by immunoassays, 128 
including inhibition studies, although they do not enable us to determine the hapten 129 
determinant involved [7,8]. Recently, BAT has proven to be a useful tool for evaluating 130 
IgE responses to these drugs, though the results seem to depend on the FQ used in 131 
the test, and are lower with MOX [8]. This, together with the fact that in recent years 132 
there has been an increase in the number of MOX reactions, in most cases severe, 133 
[6,8] make it important to analyze in depth the factors influencing these different 134 
behaviors. Based on the photolability of FQs [1-3,9] our hypothesis was that the 135 
differences found in the BAT assay between the FQs may be explained by changes 136 
induced under light exposure during the in vitro test procedure, which influences FQ 137 
degradation differently, producing a lower amount of drug-protein conjugates. 138 
The results obtained from fluorescence emission studies suggest that during 139 
BAT both FQs are able to bind to blood proteins, although free drug also remains. The 140 
data show an important photodegradation under laboratory light conditions, especially 141 
for MOX; as a consequence, lower drug-protein conjugates are also obtained. These 142 
results could be explained in terms of photostability since both FQs, although they 143 
present the same basic structure, show a different photochemical behavior due to 144 
different substituents [1,2]. Even though the presence of a fluorine atom in C-6 makes 145 
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both drugs somewhat photoreactive, the degree to which the molecules are photolabile 146 
is modulated by substituents and is directly related to the electronegativity of the 147 
substituent at C-8 [3,4]. When we analyzed the photostability in aqueous solution we 148 
observed a similar behavior for both FQs. However, important differences, with a high 149 
MOX degradation, were found when the same experiments were done in whole blood, 150 
mimicking the BAT conditions. This may be explained by the fact that the 151 
photochemical behavior also depends on the characteristics of the medium, particularly 152 
in biological environments [1,2]. Thus, in this study the complexity of the blood samples 153 
showed the unexpected facet of the reactivity of these FQs, which makes it difficult to 154 
formulate a hypothesis about the mechanisms involved. 155 
These data explain why BAT positivity under light exposure was lower with 156 
MOX (17.9%) than with CIP (46.4%), with no patients being positive solely to MOX, as 157 
previously reported [8]. However, when the BAT results were analyzed under dark 158 
conditions, there was an increase in the number of positive cases to at least one FQ, 159 
from 46.4% to 57.1%.  160 
The results obtained in BAT with the lower response observed with MOX in light 161 
(17.9%) compared to dark (35.7%) and no changes in the positivity for CIP (46.4%) 162 
correlate with the different photobehavior observed in these FQs, finding degradation 163 
after light stimulation only in MOX. Thus, in order to improve the sensitivity of BAT with 164 
MOX, this assay should be carried out under dark conditions to avoid drug 165 
photodegradation and possible misleading results.  166 
Analysis of the results depending on the culprit drug showed that in patients in 167 
whom MOX was responsible, in light conditions only 15.38% were BAT positive to this 168 
drug while 61.53% were positive to CIP. Thus, although the culprit drug was MOX, 169 
most cases were positive to CIP, as in the study by Aranda [8]. This phenomenon was 170 
not detected when CIP was the culprit drug. The reason for this was that all the positive 171 
cases to MOX were also positive to CIP, indicating that although the reaction was 172 
induced by MOX, IgE recognition was in part directed to CIP. Similar results have been 173 
published for patients with IHR to amoxicillin or amoxicillin-clavulanic acid where IgE 174 
mainly recognized benzylpenicillin [10,11]. This seems to indicate that IgE antibodies 175 
are related to the drug first exposed to (benzylpenicillin and ciprofloxacin), even if no 176 
previous reaction occurred, thus reflecting an anamnestic immune response [10,11]. 177 
The occurrence of this phenomenon is expected to decrease over time as MOX 178 
consumption increases compared to CIP, as demonstrated with betalactams where 179 
benzylpenicillin is no longer the structure most often recognized [11,12].  180 
Finally, a question remains as to whether the lower sensitivity for MOX found in 181 
BAT could also affect other in vitro tests, such as the radioimmunoassay. This may be 182 
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the case since a lower sensitivity was found with sepharose-RIA to MOX (18%) 183 
compared to that achieved with CIP (21%) in the study by Aranda [8], although further 184 
research is needed to analyze whether this phenomenon may influence other in vivo or 185 
in vitro tests.  186 
Summarizing, the data reported here suggest that MOX is sensitive to ambient 187 
laboratory light present during the performance of an in vitro assay such as BAT, 188 
producing higher drug photodegradation and, as a consequence, lower amounts of 189 
drug-protein conjugates. This shows that light exposure is a critical factor in the results 190 
of the BAT when photolabile drugs are used and it is important to bear this in mind 191 
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Table 1. Clinical characteristics and basophil activation test results of the patients 257 
Pat, Patient; SI, Stimulation Index in basophil activation test; CIP, Ciprofloxacin; MOX, 258 
Moxifloxacin; * Time between adverse reaction and study. Shaded cells indicate positive SI 259 
(greater than 3) 260 
 261 
Pat. Age Reaction Time* 
(months) 
Drug %CD63 CIP %CD63 MOX SI CIP SI MOX 
Light Dark Light Dark Light Dark Light Dark 
1 60 Urticaria 2 MOX 47.27 53.5 15.57 29.79 8.16 9.24 2.69 5.15 
2 74 Anaphylactic 
Shock 
12 MOX 5.72 41.9 13.96 3.9 0.73 5.33 1.78 0.50 
3 67 Urticaria 3 MOX 35.39 5.95 2.91 3.83 8.87 1.49 0.73 0.96 
4 58 Anaphylaxis 12 MOX 19.54 1.95 4.07 18.82 3.32 0.33 0.93 3.20 
5 67 Anaphylactic 
Shock 
2 MOX 40.47 42.86 23.96 18.77 6.30 6.68 3.73 2.92 
6 24 Anaphylaxis 3 MOX 26.27 59.55 12.94 99.98 4.99 8.74 2.42 18.72 
7 31 Anaphylaxis 12 MOX 23.3 40.94 6.11 48.21 4.13 6.27 1.08 8.55 
8 44 Anaphylactic 
Shock 
7 MOX 18.75 3.81 4.39 9.85 2.83 0.58 0.71 1.49 
9 65 Anaphylaxis 3 MOX 7.83 12.4 10.58 10.05 1.87 2.97 2.53 2.41 
10 59 Urticaria 14 MOX 24.12 20.59 5.96 21.55 4.04 3.45 1 3.61 
11 18 Anaphylaxis 1 MOX 5.05 0 3.63 0.56 0.71 0 0.51 0.08 
12 45 Anaphylaxis 1 MOX 1.41 0.70 0.75 1.27 0.30 0.15 0.16 0.27 
13 63 Anaphylaxis 4 MOX 31.27 23.42 22.92 15.62 5.50 4.12 4.03 3.08 
14 41 Anaphylaxis 3 CIP 25.45 11.61 21.23 16.17 2.99 1.37 2.50 1.90 
15 39 Anaphylaxis 12 CIP 30.26 51.19 10.95 9.86 5.31 8.98 1.92 1.73 
16 16 Anaphylaxis 2 CIP 1.56 23.81 0.79 3.18 0.32 4.94 0.16 0.66 
17 58 Anaphylaxis 10 CIP 3.19 15.24 4.97 24.64 0.59 2.83 0.92 4.58 
18 16 Anaphylaxis 10 CIP 9.72 39.82 9.68 75.51 1.72 7.06 1.72 13.39 
19 39 Anaphylaxis 3 CIP 23.53 3.23 33.33 24.29 3.95 0.54 5.59 4.08 
20 53 Anaphylaxis 1 CIP 17.06 2.67 18.6 1.86 3.12 0.49 3.40 0.34 
21 23 Anaphylaxis 16 CIP 34.88 19.31 19.43 20.43 6.82 3.78 3.80 4 
22 37 Anaphylaxis 10 CIP 7.74 4.01 10.9 4.63 1.37 0.71 1.93 0.82 
23 41 Urticaria 1 CIP 2.98 4.12 3.5 8.15 0.63 0.87 0.74 1.72 
24 35 Urticaria 12 CIP 12.59 31.92 7.51 6.15 2.23 5.65 1.33 1.09 
25 67 Anaphylaxis 3 CIP 11.2 11.19 5.99 6.7 2.33 2.33 1.25 1.39 
26 22 Anaphylaxis 5 CIP 4.3 8.87 8.37 9.94 0.83 1.71 1.61 1.92 
27 47 Urticaria 12 CIP 6.5 7.75 6.48 3.74 1.22 1.45 1.21 1.34 
28 57 Urticaria 3 CIP 18.1 18.46 0.93 1.69 3.20 3.26 0.16 0.37 
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 262 
FIGURES  263 
Figure 1. Mean and standard deviation of emission fluorescence spectra of 264 
ciprofloxacin and moxifloxacin in light and dark conditions, obtained from two different 265 
fractions, greater and lower than 3000 Da. 266 
Figure 2. Basophil activation test dose response curves for ciprofloxacin and 267 
moxifloxacin in 16 patients, 8 with a reaction to MOX and 8 with a reaction to CIP and 268 
15 controls in light and dark conditions. Results are expressed as stimulation index 269 
(SI).  270 
 271 
